четверг, 16 июня 2016 г.

Merck's Keytruda prolongs life in big lung-cancer study

Merck's Keytruda prolongs life in big lung-cancer study


Advanced lung cancer patients who took Merck & Co's Keytruda immuno-oncology medicine in a large trial and were previously untreated went longer without their disease worsening and showed a survival advantage over those given standard chemotherapy, the drugmaker said on Thursday. An independent data monitoring board recommended that the late-stage trial be stopped due to the favorable results, Merck said, thereby allowing patients who were taking chemotherapy to switch over to the company's treatment.



from Biotech News